drugset / Trial / NCT00895128

Study of Erlotinib in Combination With Dasatinib

NCT00895128

Phase 1 Completed 65 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of Tarceva (erlotinib hydrochloride) that can be given in combination with Sprycel (dasatinib). The safety of this drug combination will also be studied.

Timeline

Start
2009-04
Primary completion
2015-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 50 mg Oral
Subject Erlotinib Small molecule 100 mg Oral
Subject dasatinib anhydrous Small molecule 50 mg Oral